Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis
ConclusionsFor patients with EGFR-mutant NSCLC with LM, CSF supernatant is a valuable source for EGFR mutation testing and may provide important information. (Source: Targeted Oncology)
Source: Targeted Oncology - February 10, 2021 Category: Cancer & Oncology Source Type: research
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
ConclusionsLDH and S100B are suitable serum biomarkers during therapy with BRAFi. S100B shows stronger correlation with response and exhibits more accuracy in predicting PD. Close biomarker monitoring with S100B is recommended during treatment with BRAFi to detect PD early. (Source: Targeted Oncology)
Source: Targeted Oncology - February 8, 2021 Category: Cancer & Oncology Source Type: research
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
ConclusionsFirst-line osimertinib treatment resulted in a clinically meaningful PFS and OS benefit versus comparator EGFR TKI in Chinese patients with EGFRm advanced NSCLC. Safety data were consistent with the known safety profile of osimertinib.Clinical Trial RegistrationClinicalTrials.gov NCT02296125, registered 20 November 2014 (Source: Targeted Oncology)
Source: Targeted Oncology - February 5, 2021 Category: Cancer & Oncology Source Type: research
The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma
AbstractHepatocellular carcinoma (HCC) is one of the most common cancers and a main cause of cancer-associated death worldwide. Even with the successful launch of sorafenib for the clinical treatment of HCC in 2007, the long-term survival for patients with HCC is still suboptimal, largely due to the occurrence of primary or acquired drug resistance. With an improved understanding of the molecular pathophysiology and tumor heterogeneity of HCC, therapeutic options have been evolving rapidly in recent years. While lenvatinib, cabozantinib, regorafenib, and the monoclonal antibody ramucirumab, as well as the immune checkpoint...
Source: Targeted Oncology - February 2, 2021 Category: Cancer & Oncology Source Type: research
Vaccine Therapies for Cancer: Then and Now
AbstractThere are strong biologic and preclinical rationales for the development of therapeutic cancer vaccines; however, the clinical translation of this treatment strategy has been challenging. It is now understood that many previous clinical trials of cancer vaccines used target antigens or vaccine designs that inherently lacked sufficient immunogenicity to induce clinical responses. Despite the historical track record, breakthrough advances in cancer immunobiology and vaccine technologies have supported continued interest in therapeutic cancer vaccinations, with the hope that next-generation vaccine strategies will ena...
Source: Targeted Oncology - January 29, 2021 Category: Cancer & Oncology Source Type: research
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers
ConclusionsAbemaciclib was well tolerated and the safety and PK profiles in Chinese patients were comparable to those previously reported in non-Chinese populations. Preliminary antitumor activity was observed.ClinicalTrials.gov identifierNCT02919696. (Source: Targeted Oncology)
Source: Targeted Oncology - January 25, 2021 Category: Cancer & Oncology Source Type: research
Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
ConclusionsThe development of irAEs might be associated with survival outcomes with nivolumab treatment in patients with AGC. (Source: Targeted Oncology)
Source: Targeted Oncology - January 21, 2021 Category: Cancer & Oncology Source Type: research
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
ConclusionsThe combined analysis of these studies confirms the objective tumor responses and improvements in PFS observed in the initial phase III trial, providing further support for the clinical benefit of sunitinib in patients with advanced panNETs.ClinicalTrials.gov IdentifiersNCT00428597 and NCT01525550. (Source: Targeted Oncology)
Source: Targeted Oncology - January 7, 2021 Category: Cancer & Oncology Source Type: research
Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
ConclusionsLifetime smoking exposure plays a significant role in the effectiveness of pembrolizumab in patients with metastatic UC. (Source: Targeted Oncology)
Source: Targeted Oncology - January 5, 2021 Category: Cancer & Oncology Source Type: research
Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers
ConclusionsThe majority of uterine and ovarian cancers (93%) did not have molecular alterations with corresponding Food and Drug Administration-approved treatments. Even in patients with a potentially actionable alteration, gynecologic oncologists were more likely to choose an alternative therapy. Further investigation is warranted to determine which patients with uterine and ovarian cancer are most likely to benefit from molecular tumor profiling and the ideal timing of testing. The potential to identify effective therapeutic options in a minority of patients needs to be balanced with the current limited clinical applicab...
Source: Targeted Oncology - January 5, 2021 Category: Cancer & Oncology Source Type: research
Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
AbstractPROteolysis Targeting Chimeras (PROTACs) are a family of heterobifunctional small molecules that specifically target cellular proteins for degradation. Given that their mode of action is distinct from that of small-molecule inhibitors widely used in clinical practice, PROTACs have the potential to improve current cancer therapies. Multiple studies have suggested that PROTACs exhibit enhanced pharmacodynamics and reduced toxicity both in vitro and in vivo compared to clinically relevant small-molecule kinase inhibitors. In addition, PROTACs have been reported to be less prone to mutation-mediated drug resistance in ...
Source: Targeted Oncology - December 28, 2020 Category: Cancer & Oncology Source Type: research
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
ConclusionsThe maximum tolerated dose of rucaparib is 500 mg twice daily when co-administered with bevacizumab. The plasma concentration –time profiles of rucaparib in combination with bevacizumab suggest no pharmacokinetic interactions between the drugs. The randomized phase II portion of MITO 25 will further investigate rucaparib maintenance treatment with or without bevacizumab in patients with newly diagnosed stage III–IV ova rian cancer who responded to carboplatin-paclitaxel chemotherapy with or without bevacizumab.Trial RegistrationClinicalTrials.gov identifier NCT03462212; registered March 2018. (Source: Targeted Oncology)
Source: Targeted Oncology - December 28, 2020 Category: Cancer & Oncology Source Type: research
Correction to: SB8: A Bevacizumab Biosimilar
The article SB8: A Bevacizumab Biosimilar, written by Yahiya Y. Syed, was originally published (Source: Targeted Oncology)
Source: Targeted Oncology - December 11, 2020 Category: Cancer & Oncology Source Type: research
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
ConclusionsIn this real-world study, adult cHL patients initiated on pembrolizumab had significantly lower rates of all-cause and cHL-related hospitalizations compared to patients initiated on nivolumab. (Source: Targeted Oncology)
Source: Targeted Oncology - December 7, 2020 Category: Cancer & Oncology Source Type: research
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
ConclusionA higher allele frequency ofEGFR mutations, particularlyEGFR-activating mutations, in plasma ctDNA is a poor prognostic marker. Further studies on the clinical utility of liquid biopsy are needed. (Source: Targeted Oncology)
Source: Targeted Oncology - December 3, 2020 Category: Cancer & Oncology Source Type: research
